InvestorsHub Logo
Followers 1
Posts 269
Boards Moderated 0
Alias Born 05/08/2017

Re: ohm20 post# 54412

Friday, 01/31/2020 12:19:33 PM

Friday, January 31, 2020 12:19:33 PM

Post# of 232245
Ohm,

You hit the nail on the head.

Leronlimab just partially inhibits the CCR5 receptor and still allows an immune response.

. This difference is crucial for SAE's as you have pointed out.

Also, is an antibody and can pass through the brain barrier (as opposed to a "small particle" antagonist as Maraviroc/Variviroc which can't.)

Also, several modes of operation:

Angiogenesis
Macrophage polarization
Apoptosis
Inhibition of CCR5+ CTC's

This is worth many lives down the road (and is worth billions)

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News